SutroVax raises $64M with plans to challenge Pfizer’s megablockbuster Prevnar 13 for the heavyweight title in vaccines
When SutroVax was spun out of Sutro about four years ago, the biotech took along a conjugation platform that was repurposed for developing a new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
